๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Selection bias in clinical trails of anaplastic glioma

โœ Scribed by Michael J. Winger; David R. Macdonald; S. Clifford Schold Jr.; Dr J. Gregory Cairncross

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
441 KB
Volume
26
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Selection bias and treatment heterogenei
Selection bias and treatment heterogeneity in clinical trials
โœ Nicholas T. Longford ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 151 KB ๐Ÿ‘ 2 views

A common perception about many commercially available medical treatments is that they are e!ective for every patient having the relevant indication and that developers have provided the regulatory authorities with evidence of such a property. We show that the standard of evidence is much lower and t

Induction of apoptosis in glioma cell li
Induction of apoptosis in glioma cell lines by TRAIL/Apo-2l
โœ Mian Wu; Asha Das; Yan Tan; Cong-ju Zhu; Taian Cui; Meng Cheong Wong ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 230 KB ๐Ÿ‘ 1 views

TRAIL/Apo-2L, a novel cytokine, is a member of the tumor necrosis factor (TNF) family and serves as an extracellular signal triggering apoptosis. TRAIL/Apo-2L is capable of killing various transformed cells but not unstimulated primary T cells. In this study, five human glioma cells (U87, U118, U178